April 6, 2017
Hikma, Jazz settle for Xyrem patent litigation
Hikma Pharmaceuticals and Jazz Pharmaceuticals have found a mutual language regarding a Jazz’s Xyrem patent litigation.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
April 5, 2017
Heptares trigers milestone payment from AstraZeneca
Sosei Group Corporation’s subsidiary Heptares Therapeutics got milestone payment from AstraZeneca for working together on an immuno-oncology project.
April 5, 2017
BD buys Israel’s CME
BD (Becton, Dickinson and Company), a medical technology company, has completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems manufacturer.
April 5, 2017
Radiopharmaceuticals market could double up in 4 years
According to the report, the global market radiopharmaceuticals were valued at nearly $5.1 billion and $5.7 billion in 2014 and 2015, respectively.
April 4, 2017
FDA will look into Janssen’s sNDA for ibrutinib
The U.S. FDA will review a supplemental New Drug Application for Janssen’s Imbruvica for chronic graft-versus-host-disease after failed certain therapies.
April 4, 2017
FDA OK’s Teva’s Huntington’s disease drug
U.S. Food and Drug Administration (FDA) has approved Teva’s Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD).
April 3, 2017
FDA grants Kitov waiver for New Drug Application filing fee
Kitov Pharmaceuticals Holdings Ltd, a NASDAQ and TASE listed innovative biopharmaceutical company, said Monday that that the U.S. Food and Drug Administration (FDA) has granted Kitov a waiver related to the $2,038,100 New Drug Application filing fee for Kitov’s patented combination of …
April 3, 2017
Incyte, Bristol-Myers Squibb move epacadostat plus Opdivo combination into pivotal studies
Bristol-Myers Squibb and Incyte Corporation will evaluate combination of epacadostat with Opdivo in advancing a clinical development program into phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.
April 3, 2017
Once-weekly semaglutide lowers blood glucose and weight with type 2 diabetes patients
Novo Nordisk said Monday that once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment.
April 3, 2017
Two new e-tailers for InnovaDerma’s products
InnovaDerma, a UK developer of life sciences, beauty and personal care products has secured new e-tailer distribution deals.